X4 Pharmaceuticals shares surge 10.11% intraday after European Medicines Agency recommends mavorixafor approval for WHIM syndrome in EU.

X4 Pharmaceuticals surged 10.11% intraday following the announcement of a positive European Medicines Agency opinion recommending marketing authorization for mavorixafor in WHIM syndrome, positioning it as the first therapy for this rare condition in the EU. The company also highlighted progress in its pivotal 4WARD Phase 3 trial for chronic neutropenia, with enrollment on track to complete by Q3 2026, and confirmed a cash runway through 2028. While Q4 earnings and revenue fell short of profitability, the regulatory milestone and clinical trial advancements—key drivers for biotech valuation—overshadowed the financial results, signaling near-term commercial potential and de-risking long-term growth prospects.